EP
STRO icon

Eversept Partners’s Sutro Biopharma STRO Stock Holding History

Eversept Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.82M Sell
73,161
-120,410
-62% -$2.18M 0.1% 91
2025
Q4 		$2.24M Sell
193,571
-35,560
-16% -$337K 0.11% 85
2025
Q3 		$1.99M Sell
229,131
-95
-0% -$808 0.14% 70
2025
Q2 		$1.64M Hold
229,226
– – 0.15% 55
2025
Q1 		$1.49M Buy
229,226
+159,785
+230% +$2.52M 0.15% 49
2024
Q4 		$1.28M Sell
69,441
-114,758
-62% -$3.5M 0.11% 60
2024
Q3 		$6.37M Buy
184,199
+10,286
+6% +$403K 0.44% 35
2024
Q2 		$5.1M Buy
173,913
+64,771
+59% +$2.56M 0.35% 42
2024
Q1 		$6.17M Buy
109,142
+3,496
+3% +$154K 0.41% 44
2023
Q4 		$4.53M Buy
105,646
+28,682
+37% +$910K 0.4% 40
2023
Q3 		$2.67M Buy
76,964
+2,173
+3% +$94.7K 0.23% 57
2023
Q2 		$3.48M Buy
+74,791
New +$3.72M 0.29% 48

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Eversept Partners's STRO Position: Q1 2026 in Review

Eversept Partners reduced its Sutro Biopharma (STRO) stake by 62% in Q1 2026, selling an estimated $2.18M and leaving 73,161 shares worth $1.82M. The position accounts for 0.1% of the portfolio, ranked #91.

Eversept Partners first reported a position in STRO in Q2 2023 and has held it in 12 quarters since. The position peaked at $6.37M in Q3 2024. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Eversept Partners held 73,161 shares of Sutro Biopharma worth $1.82M as of Q1 2026.
  • Eversept Partners sold 120,410 Sutro Biopharma shares in Q1 2026, an estimated $2.18M.
  • Sutro Biopharma made up 0.1% of Eversept Partners's portfolio in Q1 2026, its #91 holding.
  • Eversept Partners first reported a position in Sutro Biopharma in Q2 2023 and has held it in 12 quarters since.
  • Eversept Partners's Sutro Biopharma position peaked at $6.37M in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.